Persistent Placoid Maculopathy: Prognosis Factors and Functional Outcomes

Ocul Immunol Inflamm. 2020 Oct 2;28(7):1136-1148. doi: 10.1080/09273948.2019.1645187. Epub 2019 Aug 16.

Abstract

Purpose: To identify prognosis factors and functional outcomes of persistent placoid maculopathy (PPM). Methods: We collected personal PPM cases and combined them with the data from the literature. Results: 68 eyes of 37 patients with PPM were analyzed, including six new cases. Twenty-six patients were men (70%) with a mean age of 51.8 years old. The mean initial visual acuity (VA) was 0.52 LogMar ± 0.55 for a mean final VA of 0.49 LogMar ± 0.51. Risk factors for poor VA included: initial VA less than 0.2 LogMar (p < .0001), cardiovascular risk factor (p = .008), autoimmune-related and/or systemic pro-inflammatory conditions (p = .003), choroidal neovascularization (p = .001), macular atrophy (p = .03) and absence of systemic corticosteroid treatment (p = .03). Conclusion: PPM is a choroidal inflammation. Identifying prognosis factors may help to guide treatment and follow-up. We showed that anti-inflammatory drugs, and anti-VEGF injections in cases of choroidal neovascularization, may lead to better outcomes.

Keywords: Choriocapillaritis; choroidal neovascularization; multimodal imaging; persistent placoid maculopathy; prognosis factors.

Publication types

  • Case Reports
  • Systematic Review

MeSH terms

  • Adult
  • Aged
  • Angiogenesis Inhibitors / therapeutic use
  • Choroidal Neovascularization / diagnosis*
  • Choroidal Neovascularization / drug therapy
  • Choroidal Neovascularization / physiopathology
  • Choroiditis / diagnosis*
  • Choroiditis / drug therapy
  • Choroiditis / physiopathology
  • Coloring Agents / administration & dosage
  • Female
  • Fluorescein Angiography
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Indocyanine Green / administration & dosage
  • Male
  • Middle Aged
  • Multimodal Imaging
  • Prognosis
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • Coloring Agents
  • Glucocorticoids
  • Immunosuppressive Agents
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Indocyanine Green